Holvita liquid colostrum can offer significant improvements in health

A number of chronically ill people with hepatitis C, including those with liver cirrhosis, have claimed a significant improvement in their health and general wellbeing while taking holvita liquid colostrum. To determine whether these anecdotal reports are representative a pilot study will begin in the latter part of 2010, involving 20 patients with hepatitis C related liver cirrhosis. Contracts have been signed between CPD Ltd and Barts and the London Hospital NHS Trust to determine the potential value of holvita TM liquid colostrum on patients with hepatitis C related liver cirrhosis. The study will look at the effects of this colostrum on the viral load, the blood picture and quality of life. The Lead Investigator will be Professor Graham Foster, Professor of Hepatology at The Centre for Digestive Diseases, Barts and The London School of Medicine and Dentistry.